Hydralazine
- Generic Name
- Hydralazine
- Brand Names
- Apresoline, Bidil
- Drug Type
- Small Molecule
- Chemical Formula
- C8H8N4
- CAS Number
- 86-54-4
- Unique Ingredient Identifier
- 26NAK24LS8
- Background
Originally developed in the 1950s as a malaria treatment, hydralazine showed antihypertensive ability and was soon repurposed. Hydralazine is a hydrazine derivative vasodilator used alone or as adjunct therapy in the treatment of hypertension and only as adjunct therapy in the treatment of heart failure. Hydralazine is no longer a first line therapy for these indications since the development of newer antihypertensive medications.
Hydralazine hydrochloride was FDA approved on 15 January 1953.
- Indication
Hydralazine is indicated alone or adjunct to standard therapy to treat essential hypertension. A combination product with isosorbide dinitrate is indicated as an adjunct therapy in the treatment of heart failure.
- Associated Conditions
- Heart Failure, Hypertension, Essential Hypertension, Hypertensive crisis, Severe Hypertension
African-American Heart Failure Trial
- Conditions
- Congestive Heart Failure
- First Posted Date
- 2002-10-21
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Nitromed
- Target Recruit Count
- 1100
- Registration Number
- NCT00047775
- Locations
- 🇺🇸
Minneapolis VA Medical Center, Minneapolis, Minnesota, United States
🇺🇸Saint Vincents Hospital and Medical Center, New York, New York, United States
🇺🇸Boston Medical Center, Boston, Massachusetts, United States
Systolic Hypertension in the Elderly Program (SHEP) (Pilot Study)
- Conditions
- Cardiovascular DiseasesHeart DiseasesHypertensionVascular Diseases
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.